Stock Evaluator: Merck KGaA (MKKGY)

Merck KGaA MKKGY

$33.17 0.02 0.06%
July 31, 2026 3:50:06 PM EST November 10, 2021 Volume: 25,282
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

Commentary & Analysis


Financial Summary

Share Statistics MKKGY Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $71,587.8 $579.1 95%
Shares Out (Mil) 500.2 43.0 89%
Institutional Ownership 50.0% 84.3% 30%
Float (Mil) 129.2 46.8 66%
Beta 0.78 0.62 46%
Avg Daily Volume (000s) 35 285 25%
Price Change
(52-week)
30.1% 63.8% 69%
Growth MKKGY Industry
Median
Percentile
(All Stocks)
Sales (5yr) 2.9% 6.7% 27%
Net Income (5yr) 4.7% (1.4%) 47%
EPS (5yr) 4.7% 14.9% 38
Dividends (5yr) 8.6% 0.0% 92%
Cash Flow (5yr) (17.3%) (14.9%) 41%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS $0.471 $1.875 $2.094
Month Ago EPS $2.303 $9.199 $9.960
# Rev Up na 1 na
# Rev Down na 0 na
Three Months Ago EPS $2.341 $8.912 $9.867
Year/Year Chg na (73.4%) na
Financials MKKGY Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $24,162 $272 93%
Net Income (TTM) (Mil) $2,920 ($11) 94%
EPS (TTM) $6.720 ($0.500) 91%
Operating Cash Flow (TTM) (Mil) $4,836 ($6) 95%
Net Cash Flow (TTM) (Mil) $2,039 $4 97%
Long-Term Debt (Q1) (Mil) $12,455 $7 93%
Enterprise Value (Q1) (Mil) $70,350 $522 94%
Valuation MKKGY Industry
Median
Percentile
(All Stocks)
P/B na 2.73 na
P/E na 20.5 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios MKKGY Industry
Median
Percentile
(All Stocks)
Gross Margin 58.9% 65.9% 72%
Net Margin 12.1% 0.7% 68%
ROA 5.1% (24.6%) 73%
ROE 8.8% (19.7%) 54%
Liabilities to Assets 43.8% 35.5% 35%
F-Score na 3 na

Merck KGaA did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors